Skip to content

Survivorship and late effects

TL;DR — Colorectal-cancer survivorship includes surveillance, bowel/sexual/urinary function, neuropathy, stoma care, psychosocial health and financial burden. A population study found major low anterior resection syndrome (LARS) in 53.1% at mean 6.7 years after rectal surgery, with worse quality of life (Pieniowski 2020, PMID 32530135). Permanent colostomy does not uniformly produce worse quality of life than an anastomosis; severe LARS can make “sphincter preservation” a misleading functional endpoint (Pachler 2012, PMID 23235607). Oxaliplatin neuropathy may persist long after treatment, while pelvic therapy can cause sexual and urinary dysfunction that guidelines address inconsistently (Fernandes 2024, PMID 39361213; Wiltink 2020, PMID 32025805). Surveillance can detect resectable recurrence, but CEA, CT and colonoscopy have different targets and false-positive burdens (Shinkins 2018, PMID 29579327). Financial toxicity is common and should be measured as an outcome, not treated as a social footnote (Azzani 2024, PMID 38182993).

Survivorship begins at diagnosis

“Survivor” can mean anyone from diagnosis onward or someone after curative treatment. This page focuses on people living after treatment with or without ongoing disease.

Domain Early need Late need
Cancer control Complete staging/treatment Recurrence and second-cancer surveillance
Bowel function Leak, ileus, diarrhea, stoma teaching LARS, clustering, incontinence, hernia
Neurologic Acute cold sensitivity Persistent sensory neuropathy
Sexual/urinary Counseling before pelvic treatment Dysfunction rehabilitation
Psychosocial Distress and decision support Fear of recurrence, identity, return to work
Financial Leave, transport and copay Debt, employment and insurance
Lifestyle Nutrition during treatment Activity, weight, smoking/alcohol support

Survivorship care guidelines recommend coordinated oncology–primary care follow-up with a treatment summary, surveillance plan and late-effect management (El-Shami 2015, PMID 26348643; Hardiman 2021, PMID 33591043).

Surveillance purposes

Modality Primary target What it misses
History/examination Symptoms, functional effects, recurrence clues Asymptomatic disease
CEA Secretory recurrence signal CEA-nonsecretory recurrence
CT chest/abdomen/pelvis Distant/local structural recurrence Small/early molecular disease
Colonoscopy Metachronous cancer and polyps Most distant recurrence
Pelvic MRI/endoscopy Rectal/watch-and-wait local disease Distant disease

More testing is not automatically better. A surveillance program should increase detection of recurrence amenable to curative treatment without overwhelming patients with false positives and radiation.

US Multi-Society Task Force guidance separates colonoscopy after resection from systemic recurrence surveillance (Kahi 2016, PMID 26892199). ESGE/ESDO guidance likewise emphasizes a high-quality perioperative colon exam and scheduled post-resection colonoscopy (Hassan 2019, PMID 30722071).

CEA and imaging

CEA trends in FACS data discriminated recurrence better than isolated values, but repeated testing accumulated false alarms and no threshold captured every recurrence (Shinkins 2018, PMID 29579327). Meta-analysis of follow-up tests found heterogeneous sensitivity/specificity across CEA, imaging and clinical review (Liemburg 2021, PMID 33704843).

CEA pattern Interpretation
Stable normal after secretory baseline Reassuring but not exclusionary
Sustained rise Repeat/confirm and image
Single small elevation Consider smoking, inflammation and assay variation
Normal despite symptoms Investigate symptoms; do not dismiss

Surveillance adherence varies widely; a systematic review found discrepancies between recommended colonoscopy, imaging and CEA use, with both underuse and overuse (Dawood 2023, PMID 36806402).

Bowel dysfunction after colon resection

Right colectomy can cause looser stool from reduced absorptive capacity and bile-acid malabsorption. Left/sigmoid resection may increase frequency or urgency. Adhesions, small-bowel bacterial overgrowth, pancreatic disease, medication and recurrence can mimic treatment effects.

Evaluation should phenotype stool frequency, consistency, urgency, nocturnal symptoms, bleeding, pain, weight change and dietary triggers rather than label every symptom “post-surgical.”

Low anterior resection syndrome

LARS includes urgency, clustering, frequency, incontinence and evacuation difficulty after rectal resection. The international consensus definition incorporates consequences and unpredictability, not only individual symptoms (Keane 2020, PMID 32032141).

The LARS score uses five items—flatus incontinence, liquid-stool leakage, frequency, clustering and urgency—to classify no/minor/major syndrome (Emmertsen 2012, PMID 22504191).

Risk factor Mechanism
Low anastomosis Smaller reservoir and sphincter proximity
Pelvic radiation Fibrosis, motility and sensory injury
Anastomotic leak Pelvic inflammation/scarring
Temporary diverting stoma Disuse and delayed adaptation
Longer follow-up Some adaptation, but chronic symptoms persist

Population-based data found 53.1% major LARS and 22.6% no LARS at mean 6.7 years; major LARS strongly reduced quality of life (Pieniowski 2020, PMID 32530135). Systematic review documented inconsistent definitions before consensus, limiting older prevalence comparison (Keane 2017, PMID 28612460).

Management is staged: diet/fiber individualized to phenotype, antidiarrheals, pelvic-floor rehabilitation, transanal irrigation and, for refractory severe symptoms, neuromodulation or stoma discussion. Evidence for each sequence is less robust than prevalence evidence (Nguyen 2020, PMID 32749603).

LARS can also occur after colectomy, though rectal resection carries the dominant burden (Meurs 2023, PMID 37369860).

Stoma outcomes

A stoma can be temporary or permanent, planned or emergency. Outcomes depend on preoperative marking, education, appliance access, body contour, dexterity, skin health and specialist nursing.

Stoma issue Manifestation Support need
Peristomal skin injury Pain, leakage, dermatitis Appliance fitting and skin care
High output Dehydration/renal injury Fluid/electrolyte plan and medication
Parastomal hernia Bulge, appliance difficulty Support, surgery selection
Retraction/prolapse Leakage or obstruction Stoma review/surgery
Body image/intimacy Avoidance and distress Counseling and peer support
Access/cost Rationed appliances Health-system coverage

Cochrane review found no consistent overall quality-of-life superiority for rectal resection without permanent stoma versus permanent colostomy; study quality and heterogeneity were substantial (Pachler 2012, PMID 23235607). The meaningful comparison is good-function anastomosis versus severe LARS versus well-supported stoma.

After stoma reversal, qualitative synthesis found bowel unpredictability, inadequate preparation and unmet information/support needs (Pape 2021, PMID 34543812).

Neuropathy

Oxaliplatin causes acute cold-triggered paresthesia and cumulative sensory neuropathy. Acute symptoms usually resolve between cycles; chronic numbness, pain, proprioceptive loss and fine-motor impairment can persist.

Phase Clinical signal Action
Acute Cold dysesthesia, jaw/throat sensations Education and exposure avoidance
Cumulative Persistent numbness between cycles Dose reduction/stop oxaliplatin
Late Balance, falls, pain, dexterity problems Rehabilitation, safety and symptom treatment

Preventive supplements have not consistently worked; a systematic review found insufficient evidence for goshajinkigan and potential heterogeneity/harm signals (Kuriyama 2018, PMID 29280005). Duration de-escalation is one of the most effective neuropathy-prevention strategies in adjuvant therapy.

Persistent symptoms should be assessed for diabetes, B12 deficiency, spinal disease and other neuropathy causes rather than automatically attributed to chemotherapy.

Sexual function

Pelvic surgery can injure autonomic nerves; radiation causes vascular, neural and tissue fibrosis; menopause, androgen change, stoma/body image and relationship factors interact.

Men may experience erectile/ejaculatory dysfunction; women may experience vaginal dryness/stenosis, dyspareunia and reduced desire. All genders can experience altered intimacy and identity.

Systematic review found long-term non-gastrointestinal symptom burden—including sexual and urinary effects—substantial but inconsistently measured (Fernandes 2024, PMID 39361213). Guidelines often provide limited concrete management recommendations (Wiltink 2020, PMID 32025805).

Radiation counseling is frequently inadequate; review of anorectal radiation literature found poor preparation of patients for sexual dysfunction (Wallington 2021, PMID 32777386). Intervention evidence for women after rectal/anal pelvic treatment remains sparse (Arthur 2018, PMID 29947348).

Urinary function

Pelvic autonomic injury can cause retention, incomplete emptying, urgency or incontinence. Acute postoperative retention should be distinguished from chronic dysfunction.

Red flags include rising creatinine, recurrent infection, hydronephrosis and inability to void. Pelvic-floor therapy, medication and urologic evaluation depend on phenotype.

Fatigue, cognition and sleep

Fatigue may persist after chemotherapy and surgery. Contributors include anemia, sleep disruption, mood, deconditioning, pain, endocrine disease, nutritional deficiency and ongoing inflammation.

Cancer-survivor systematic review found multiple long-term symptom domains persist after treatment and are often under-recognized in routine follow-up (Harrington 2010, PMID 20848873).

Fear of recurrence and psychosocial burden

Scan cycles, CEA results and new bowel symptoms can trigger recurrent anxiety. Reassurance without evaluation is unhelpful; excessive testing can amplify rather than resolve uncertainty.

Qualitative meta-synthesis describes survivors’ needs for clear information, continuity, symptom validation and support beyond the acute-treatment endpoint (Rutherford 2020, PMID 32335745). Highly intensive procedures such as cytoreductive surgery also impose prolonged recovery and caregiver burden (Raichurkar 2025, PMID 40295419).

Financial toxicity and work

Costs include direct bills, travel, stoma supplies, dietary/medication costs and lost earnings. A systematic review found both subjective distress and objective financial burden across colorectal cohorts, with wide measurement heterogeneity (Azzani 2024, PMID 38182993).

Metastatic treatment costs vary dramatically by country, biologic and line, and often omit patient time and caregiver work (Bhimani 2022, PMID 36063775).

Risk point Preventive response
Before treatment Employment/leave, transport and insurance counseling
During treatment Cost screening and social-work navigation
Return to work Graded duties and bowel/stoma accommodations
Chronic toxicity Disability documentation and rehabilitation

Watch-and-wait survivorship

Avoiding TME can preserve function but replaces surgical recovery with intensive surveillance and regrowth anxiety. Long-term watch-and-wait cohorts report favorable function and quality of life relative to resection, with selection caveats (Custers 2023, PMID 36988922).

Surveillance burden must be included when counting “organ preservation.”

Care-plan minimum dataset

  • Diagnosis, stage, molecular profile and hereditary implications.
  • Surgery and anastomosis/stoma details.
  • Radiation field/dose and systemic cumulative doses.
  • Recurrence surveillance schedule with owner.
  • Colonoscopy schedule.
  • Bowel, neuropathy, sexual, urinary and psychosocial baseline.
  • Emergency symptoms and contact route.
  • Primary-care preventive care and comorbidity plan.
  • Employment, financial and appliance-access needs.

Open questions

  • Which early rehabilitation program prevents persistent major LARS? (Pieniowski 2020, PMID 32530135)
  • How should severe LARS versus permanent stoma be compared in shared decisions? (Pachler 2012, PMID 23235607)
  • Which surveillance intensity improves curative salvage without excess false positives? (Liemburg 2021, PMID 33704843)
  • Which interventions prevent chronic oxaliplatin neuropathy beyond dose limitation? (Kuriyama 2018, PMID 29280005)
  • Can a core survivorship outcome set make sexual, urinary and financial effects visible in trials? (Wiltink 2020, PMID 32025805)

References

  1. Pieniowski EHA, et al. Prevalence of low anterior resection syndrome and impact on quality of life after rectal cancer surgery: population-based study. BJS Open. 2020;4(5):935-942. PMID 32530135
  2. Pachler J, Wille-Jørgensen P. Quality of life after rectal resection for cancer, with or without permanent colostomy. Cochrane Database Syst Rev. 2012;12(12):CD004323. PMID 23235607
  3. Fernandes D, et al. Non-gastrointestinal symptom burden following colorectal cancer treatment-a systematic review. Support Care Cancer. 2024;32(10):699. PMID 39361213
  4. Wiltink LM, et al. Systematic review of clinical practice guidelines for colorectal and anal cancer: the extent of recommendations for managing long-term symptoms and functional impairments. Support Care Cancer. 2020;28(6):2523-2532. PMID 32025805
  5. Shinkins B, et al. Serum carcinoembryonic antigen trends for diagnosing colorectal cancer recurrence in the FACS randomized clinical trial. Br J Surg. 2018;105(6):658-662. PMID 29579327
  6. Azzani M, et al. Subjective and objective financial toxicity among colorectal cancer patients: a systematic review. BMC Cancer. 2024;24(1):40. PMID 38182993
  7. El-Shami K, et al. American Cancer Society Colorectal Cancer Survivorship Care Guidelines. CA Cancer J Clin. 2015;65(6):428-55. PMID 26348643
  8. Hardiman KM, et al. The American Society of Colon and Rectal Surgeons Clinical Practice Guidelines for the Surveillance and Survivorship Care of Patients After Curative Treatment of Colon and Rectal Cancer. Dis Colon Rectum. 2021;64(5):517-533. PMID 33591043
  9. Kahi CJ, et al. Colonoscopy Surveillance After Colorectal Cancer Resection: Recommendations of the US Multi-Society Task Force on Colorectal Cancer. Gastroenterology. 2016;150(3):758-768.e11. PMID 26892199
  10. Hassan C, et al. Endoscopic surveillance after surgical or endoscopic resection for colorectal cancer: European Society of Gastrointestinal Endoscopy (ESGE) and European Society of Digestive Oncology (ESDO) Guideline. Endoscopy. 2019;51(3):266-277. PMID 30722071
  11. Liemburg GB, et al. Diagnostic accuracy of follow-up tests for detecting colorectal cancer recurrences in primary care: A systematic review and meta-analysis. Eur J Cancer Care (Engl). 2021;30(5):e13432. PMID 33704843
  12. Dawood ZS, et al. Colonoscopy, imaging, and carcinoembryonic antigen: Comparison of guideline adherence to surveillance strategies in patients who underwent resection of colorectal cancer - A systematic review and meta-analysis. Surg Oncol. 2023;47:101910. PMID 36806402
  13. Keane C, et al. International Consensus Definition of Low Anterior Resection Syndrome. Dis Colon Rectum. 2020;63(3):274-284. PMID 32032141
  14. Emmertsen KJ, Laurberg S. Low anterior resection syndrome score: development and validation of a symptom-based scoring system for bowel dysfunction after low anterior resection for rectal cancer. Ann Surg. 2012;255(5):922-8. PMID 22504191
  15. Keane C, et al. Defining low anterior resection syndrome: a systematic review of the literature. Colorectal Dis. 2017;19(8):713-722. PMID 28612460
  16. Nguyen TH, Chokshi RV. Low Anterior Resection Syndrome. Curr Gastroenterol Rep. 2020;22(10):48. PMID 32749603
  17. Meurs J, et al. Low anterior resection syndrome (LARS) and quality of life after colectomy. Int J Colorectal Dis. 2023;38(1):180. PMID 37369860
  18. Pape E, et al. Experiences and needs of patients with rectal cancer confronted with bowel problems after stoma reversal: A systematic review and thematic-synthesis. Eur J Oncol Nurs. 2021;54:102018. PMID 34543812
  19. Kuriyama A, Endo K. Goshajinkigan for prevention of chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis. Support Care Cancer. 2018;26(4):1051-1059. PMID 29280005
  20. Wallington DG, Holliday EB. Preparing Patients for Sexual Dysfunction After Radiation for Anorectal Cancers: A Systematic Review. Pract Radiat Oncol. 2021;11(3):193-201. PMID 32777386
  21. Arthur EK, Wills CE, Menon U. A Systematic Review of Interventions for Sexual Well-Being in Women With Gynecologic, Anal, or Rectal Cancer. Oncol Nurs Forum. 2018;45(4):469-482. PMID 29947348
  22. Harrington CB, et al. It's not over when it's over: long-term symptoms in cancer survivors--a systematic review. Int J Psychiatry Med. 2010;40(2):163-81. PMID 20848873
  23. Rutherford C, et al. Patient-reported outcomes and experiences from the perspective of colorectal cancer survivors: meta-synthesis of qualitative studies. J Patient Rep Outcomes. 2020;4(1):27. PMID 32335745
  24. Raichurkar P, et al. Undergoing Cytoreductive Surgery for Colorectal Peritoneal Metastases: A Qualitative Exploration of the Lived Experiences of Patients and Carers. Ann Surg Oncol. 2025;32(7):5042-5050. PMID 40295419
  25. Bhimani N, et al. Cost of treating metastatic colorectal cancer: a systematic review. Public Health. 2022;211:97-104. PMID 36063775
  26. Custers PA, et al. Long-term Quality of Life and Functional Outcome of Patients With Rectal Cancer Following a Watch-and-Wait Approach. JAMA Surg. 2023;158(5):e230146. PMID 36988922